Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Mutationally activated BRAF(V600E) elicits papillary thyroid cancer in the adult mouse.

Cancer research - 1 Jun 2011

Charles Roch-Philippe, Iezza Gioia, Amendola Elena, Dankort David, McMahon Martin

Abstract excerpt

Mutated BRAF is detected in approximately 45% of papillary thyroid carcinomas (PTC). To model PTC, we bred mice with adult-onset, thyrocyte-specific expression of BRAF(V600E). One month following BRAF(V600E) expression, mice displayed increased thyroid size, widespread alterations in thyroid architecture, and dramatic hypothyroidism. Over 1 year, without any deliberate manipulation of tumor suppressor genes, all...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Carcinoma
Share to Carcinoma, Papillary
Share to Cell Transformation, Neoplastic

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Disease Models, Animal

Share to Disease Progression

Share to Proto-Oncogene Proteins B-raf

Share to Thyroid Cancer, Papillary

Share to Thyroid Neoplasms

Source

Open in PubMed Open full text

Identifiers

PMID: 21512141
DOI: 10.1158/0008-5472.CAN-10-4463
PMCID: PMC3107361

Genes

BRAF

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Mutationally activated BRAF(V600E) elicits papillary thyroid cancer in the adult mouse.PMID 21512141Read ↗

Targeted expression of BRAFV600E in thyroid cells of transgenic mice results in papillary thyroid cancers that undergo dedifferentiation.Semantic proximity Read ↗

p53 constrains progression to anaplastic thyroid carcinoma in a Braf-mutant mouse model of papillary thyroid cancer.Semantic proximity Read ↗

Activating BRAF and PIK3CA mutations cooperate to promote anaplastic thyroid carcinogenesis.Semantic proximity Read ↗

Lessons from Mouse Models of Thyroid CancerSemantic proximity Read ↗

BRAF mutation in papillary thyroid carcinoma: pathogenic role and clinical implications.Semantic proximity Read ↗

Tissue architecture delineates field cancerization in BRAFV600E-induced tumor development.Semantic proximity Read ↗

BRAF mutation in thyroid cancer.Semantic proximity Read ↗

Small-molecule MAPK inhibitors restore radioiodine incorporation in mouse thyroid cancers with conditional BRAF activationSemantic proximity Read ↗

An Animal Model Further Uncovers the Role of Mutant BrafV600E during Papillary Thyroid Cancer Development.Semantic proximity Read ↗

BRAFV600E-Associated Gene Expression Profile: Early Changes in the Transcriptome, Based on a Transgenic Mouse Model of Papillary Thyroid CarcinomaSemantic proximity Read ↗

Mouse models of thyroid cancer: A 2015 update.Semantic proximity Read ↗

Thyrotropin signaling confers more aggressive features with higher genomic instability on BRAF(V600E)-induced thyroid tumors in a mouse model.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.